Screener
Capricor Therapeutics CAPR Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
| Line item | March 31, 2026 / (unaudited) | December 31, 2025 | December 31, 2025 |
|---|---|---|---|
| STOCKHOLDERS’ EQUITY | |||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding | — | — | |
| Common stock, $0.001 par value, 100,000,000 shares authorized, 57,664,673 and 57,370,909 shares issued and outstanding, respectively | 57,665 | 57,371 | |
| Additional paid-in capital | 617,718,525 | 610,330,105 | |
| Accumulated other comprehensive income | (253,727) | 283,154 | |
| Accumulated deficit | (338,819,830) | (304,878,485) | |
| TOTAL STOCKHOLDERS’ EQUITY | 278,702,633 | 305,792,145 | |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $326,283,517 | $ | $355,949,294 |
Item 1. Financial Statements.
FAQ
- What is Capricor Therapeutics's total equity?
- Capricor Therapeutics (CAPR) reported total equity of $278.7M in Q1 2026.
- How has Capricor Therapeutics's total equity changed year-over-year?
- Capricor Therapeutics's total equity increased by 118.3% year-over-year, from $127.65M to $278.7M.
- What is the long-term trend for Capricor Therapeutics's total equity?
- Over 5 years (2020 to 2025), Capricor Therapeutics's total equity has grown at a 61.1% compound annual growth rate (CAGR), from $28.2M to $305.79M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Capricor Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude